Bausch Health Companies Inc. Amortization of Intangible Assets
Bausch Health Companies Inc. (BHC) reported Amortization of Intangible Assets of $1.90 billion for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2014-02-28
- Bausch Health Companies Inc. amortization of intangible assets for the quarter ending 2013-12-31 was $361.96M, a 20.86% increase year-over-year.
- Bausch Health Companies Inc. amortization of intangible assets for the quarter ending 2013-09-30 was $910.25M, a 317.19% increase year-over-year.
- Bausch Health Companies Inc. amortization of intangible assets for the quarter ending 2013-06-30 was $303.60M, a 43.82% increase year-over-year.
- Bausch Health Companies Inc. amortization of intangible assets for the quarter ending 2013-03-31 was $326.18M, a 60.94% increase year-over-year.
- Bausch Health Companies Inc. amortization of intangible assets for fiscal 2013 was $1.90B, a 104.20% increase from fiscal 2012.
- Bausch Health Companies Inc. amortization of intangible assets for fiscal 2012 was $931.44M, a 64.28% increase from fiscal 2011.
- Bausch Health Companies Inc. amortization of intangible assets for fiscal 2011 was $566.99M, a 147.67% increase from fiscal 2010.
- Bausch Health Companies Inc. amortization of intangible assets for fiscal 2010 was $228.93M, a 100.99% increase from fiscal 2009.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|
| 2013-12-31 | $361.96M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $1.27B derived: sum of 2 quarters · filed 2014-02-28 | $1.58B derived: sum of 3 quarters · filed 2014-02-28 | $1.90B 10-K · filed 2014-02-28 |
| 2013-09-30 | $910.25M 10-Q · filed 2013-11-01 | $1.21B derived: sum of 2 quarters · filed 2013-11-01 | $1.54B 10-Q · filed 2013-11-01 | $1.84B derived: sum of 4 quarters · filed 2014-02-28 |
| 2013-06-30 | $303.60M 10-Q · filed 2013-08-07 | $629.77M 10-Q · filed 2013-08-07 | $929.26M derived: sum of 3 quarters · filed 2014-02-28 | $1.15B derived: sum of 4 quarters · filed 2014-02-28 |
| 2013-03-31 | $326.18M 10-Q · filed 2013-05-03 | $625.66M derived: sum of 2 quarters · filed 2014-02-28 | $843.85M derived: sum of 3 quarters · filed 2014-02-28 | $1.05B derived: sum of 4 quarters · filed 2014-02-28 |
| 2012-12-31 | $299.49M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $517.67M derived: sum of 2 quarters · filed 2014-02-28 | $728.77M derived: sum of 3 quarters · filed 2014-02-28 | $931.44M 10-K · filed 2014-02-28 |
| 2012-09-30 | $218.19M 10-Q · filed 2013-11-01 | $429.29M derived: sum of 2 quarters · filed 2013-11-01 | $631.96M 10-Q · filed 2013-11-01 | $827.05M derived: sum of 4 quarters · filed 2014-02-28 |
| 2012-06-30 | $211.10M 10-Q · filed 2013-08-07 | $413.77M 10-Q · filed 2013-08-07 | $608.86M derived: sum of 3 quarters · filed 2014-02-28 | $749.18M derived: sum of 4 quarters · filed 2014-02-28 |
| 2012-03-31 | $202.67M 10-Q · filed 2013-05-03 | $397.76M derived: sum of 2 quarters · filed 2014-02-28 | $538.08M derived: sum of 3 quarters · filed 2014-02-28 | $655.32M derived: sum of 4 quarters · filed 2014-02-28 |
| 2011-12-31 | $195.09M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $335.41M derived: sum of 2 quarters · filed 2014-02-28 | $452.65M derived: sum of 3 quarters · filed 2014-02-28 | $566.99M 10-K · filed 2014-02-28 |
| 2011-09-30 | $140.32M 10-Q · filed 2012-11-05 | $257.56M derived: sum of 2 quarters · filed 2012-11-05 | $371.90M 10-Q · filed 2012-11-05 | $491.85M derived: sum of 4 quarters · filed 2013-02-28 |
| 2011-06-30 | $117.24M 10-Q · filed 2012-08-03 | $231.58M 10-Q · filed 2012-08-03 | $351.53M derived: sum of 3 quarters · filed 2013-02-28 | $389.32M derived: sum of 4 quarters · filed 2013-02-28 |
| 2011-03-31 | $114.34M 10-Q · filed 2012-05-04 | $234.29M derived: sum of 2 quarters · filed 2013-02-28 | $272.08M derived: sum of 3 quarters · filed 2013-02-28 | $307.68M derived: sum of 4 quarters · filed 2013-02-28 |
| 2010-12-31 | $119.95M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | $157.75M derived: sum of 2 quarters · filed 2013-02-28 | $193.34M derived: sum of 3 quarters · filed 2013-02-28 | $228.93M 10-K · filed 2013-02-28 |
| 2010-09-30 | $37.79M 10-Q · filed 2011-11-04 | $73.39M derived: sum of 2 quarters · filed 2011-11-04 | $108.98M 10-Q · filed 2011-11-04 | |
| 2010-06-30 | $35.59M 10-Q · filed 2011-08-08 | $71.19M 10-Q · filed 2011-08-08 | ||
| 2009-12-31 | $113.91M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |